Lovastatin sodium salt

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays.

Carboxylate form of Lovastatin (Cat. No. 438185) that is active in whole cells and cell-free assays. Lovastatin is reported to be an anti-hypercholesterolemic agent that acts as an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocks a series of biological events including activation of p21^ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21^ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G₁ phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF.

Cell permeable: yes

Primary Target
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Following reconstitution, aliquot, flush with an inert gas, and freeze (-20°C). Stock solutions in high quality ethanol are stable for up to 1 month at -20°C.

Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem.271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys.326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Carcinogenic / Teratogenic (D)